Free Trial
NYSE:ANRO

Alto Neuroscience Q3 2024 Earnings Report

Alto Neuroscience logo
$2.33 +0.05 (+1.97%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$2.28 -0.05 (-1.94%)
As of 04/25/2025 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alto Neuroscience EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.67
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Alto Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alto Neuroscience Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Alto Neuroscience's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Alto Neuroscience Earnings Headlines

Trump’s Secret Social Security Plan?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
Alto Neuroscience initiated with a Buy at H.C. Wainwright
See More Alto Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alto Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your email.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

View Alto Neuroscience Profile

More Earnings Resources from MarketBeat